Drug firm GSK fined $2.6 million for collusion

South Korea's anti-trust agency has fined drugmaker GlaxoSmithKline three billion won ($2.6 million) for conspiring with a Seoul rival over the sale of drugs, an official said Monday.

The (FTC) said GSK in 2000 offered Dong-A Pharmaceutical the exclusive right to sell its anti-nausea drug Zofran and an anti-viral medication called Valtrex.

In return, the FTC said the British-based multinational demanded that Dong-A stop selling a cheaper of Zofran which the Seoul firm had introduced in 1998.

GSK also asked that Dong-A never produce or sell any drugs that could compete against Zofran and Valtrex, Kim Jun-Ha, a FTC official involved in the case, told AFP.

"With the cheaper generics made by Dong-A taken off the market, the on patients and on the government's health insurance budget has increased," Kim said.

The FTC said in a statement it estimated GSK had made wrongful gains of about 16 billion won. It said "the two firms shared benefits that were to go to consumers".

Dong-A was fined 2.1 billion won for the collusion, the agency added.

GSK's South Korean unit called the decision "very regrettable" and "inappropriate" and said it would appeal in court.

"We simply exercised our legitimate patent rights," it said in a statement, adding that there was no illegality.

add to favorites email to friend print save as pdf

Related Stories

Generics controversy issue widens

Jun 05, 2006

A dispute between the U.S. Justice Department and Federal Trade Commission over generic drugs is reportedly widening with implications for the drug firms.

Recommended for you

Medical charity warns India over patent rules

Jan 21, 2015

Doctors without Borders on Wednesday warned the Indian government not to bow to US pressure to amend patent regulations that allow millions access to affordable medicines, ahead of a visit by President Barack Obama.

Why are some generic drugs getting so expensive?

Jan 21, 2015

More than eight out of every 10 prescriptions dispensed in the US is generic. This growth is due to a large number of top-selling drugs going off patent over the past decade, as well as innovations in t ...

Supreme Court sides with Teva in drug dispute

Jan 20, 2015

The Supreme Court on Tuesday sided with Teva Pharmaceutical Industries Ltd. in the company's high-profile patent dispute with rival firms over the top-selling multiple sclerosis drug.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.